ACC017 not checked
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Infection, Human Immunodeficiency Virus (2 trials)
- Main trialPhase 3
- “This study employs a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group, non-inferiority design. The trial will be conducted in treatment-naïve adult patients with HIV-1, using Dolutegravir Sodium Tablets as the control, to demonstrate the efficacy and safety of the core investigational drug ACC017 combined with FTC/TAF Tablets (II) compared to Dolutegravir Sodium combined with FTC/TAF Tablets (II) in treating treatment-naïve adult HIV-1 patients. After initial screening eligibility is confirmed, participants will return to the clinic on Day 1 (D1) for…”In the company’s words, NCT07711223 on ClinicalTrials.gov
Other drugs for Infection, Human Immunodeficiency Virus
- DTpaGSK · Phase 3
- Investigational varicella vaccineGSK · Phase 3
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- Yellow fever vaccineSanofi · Phase 3
- Plasmodium immunotherapyCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. · Phase 2/3
- Colgate SNaP Total 10/10Colgate Palmolive · Phase 3
Coming up2
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 18 NovPhase changed: Phase 1/2 to Phase 3 · ClinicalTrials.gov NCT07711223
- 18 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07711223
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Aug 2028 | Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1) | |
| Phase 1/2Active, not recruiting | 30 Jun 2027 | Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations | |
| Phase 1/2Completed | 28 Apr 2025 | Phase Ib/IIa Clinical Study of ACC017 Tablets | |
| Phase 1Completed | 20 May 2024 | Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026